| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 1 data readout example | ELI-002 7P (investigational AMP cancer vaccine) borderline and resectable pancreatic ductal adenocarcinoma (PDAC) | Phase 1 | — | Vaccines | Oncology | ||
phase 1 data readout example | ELI-002 7P (investigational AMP cancer vaccine) borderline and resectable pancreatic ductal adenocarcinoma (PDAC) | Phase 1 | — | Vaccines | Oncology | ||
phase 1 data readout example | ELI-002 7P (investigational AMP cancer vaccine) borderline and resectable pancreatic ductal adenocarcinoma (PDAC) | Phase 1 | — | Vaccines | Oncology |
Recent Updates
Recently added Catalysts
Elicio Therapeutics, Inc.$3.98
-0.13 (-3.16%)
F 16Pipeline Score Richly Valued Biotech · Commercial
Market Cap
189.91 M
EPS
-2.34
P/E Ratio
-
Value Trade
1.82 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
6.76 M
Operating CF
-11.64 M
Total Assets
22.69 M
Total Liabilities
24.13 M
Equity
-1.44 M
D/E Ratio
12,345
-6.92 %
Week
-18.31 %
1 Month
14.37 %
3 Month
23.6 %
6 Month
-93.83 %
5 Year
-94.35 %
All Time
Cash Data
Cash Position
14.95 M
Monthly Burn
3.88 M
Runway
2.7 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
760.98 K
52 Week Range
5.80 - 14.93
% held by Insiders
31.1 %
% held by Institutions
13.98 %
Enterprise Value
189.30 M
Total Shares
19.09 M
Short %
25.81 %
Float Shares
7.35 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F16
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.0x
rNPV / MCap Top 14%
Micro Cap (rank 779 of 905)
Percentile RankElicio Therapeutics, Inc. has significant pipeline risk (16/100), with $20M risk-adjusted pipeline value, led by ELI-002 7P in Pancreatic Ductal Adenocarcinoma (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELI-002 7P Small molecule | Pancreatic Ductal Adenocarcinoma | Phase 1 | NCT05726864 | 5% | $12M | ACTIVE NOT_RECRUITING | 158 | VERY_FAST | C (52) | Nov 1, 2026 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ELI-002 7P | pancreatic ductal adenocarcinoma | Phase 2 | 2025-08-06 | |||
ELI-002 7P | pancreatic ductal adenocarcinoma | Phase 2 | 2025-08-06 | |||
ELI-002 7P | pancreatic ductal adenocarcinoma | Phase 2 | 2025-08-06 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ELTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ELTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ELTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ELTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ELTX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ELTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ELTXElicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
Elicio Therapeutics reported promising results from its Phase 2 AMPLIFY-7P study, where three patients with metastatic mKRAS pancreatic cancer achieved complete responses after receiving ELI-002 7P followed by nivolumab therapy. These findings suggest that ELI-002 7P may enhance the effectiveness of checkpoint inhibitors, leading to plans for a Phase 1 study to further investigate this combination. The company aims to refine its development strategy based on these observations.
Read more →ELTXElicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
Elicio Therapeutics reported mixed results from its Phase 2 AMPLIFY-7P study of ELI-002 7P in adjuvant pancreatic cancer. While the study did not meet its primary endpoint of disease-free survival (DFS) in the intent-to-treat population, post-hoc analyses indicated significant DFS improvement in patients with lower residual disease. The company plans to refine its Phase 3 development strategy focusing on this subgroup, supported by promising immune response data.
Read more →ELTXElicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology
Elicio Therapeutics announced the publication of a peer-reviewed manuscript in Science Advances detailing its AMP-DNA adjuvant technology. The research highlights robust immune responses initiated through targeted delivery to lymph nodes, showcasing improved efficacy over existing adjuvants. Notable findings include potent T cell activation and durable immune memory observed for at least nine months in preclinical models, including non-human primates. These developments signify a meaningful advancement in Elicio's immunotherapy pipeline aimed at treating various cancers.
Read more →ELTXElicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Elicio Therapeutics reported its Q1 2026 financial results, highlighting significant fundraising efforts totaling $13 million. The company is focused on its Phase 2 AMPLIFY-7P trial for ELI-002 7P in pancreatic cancer, with a primary disease-free survival analysis expected mid-2026. Despite a slight increase in net loss, Elicio's cash runway is projected to support operations through Q4 2026.
Read more →ELTXElicio Therapeutics to Present at the Bank of America Healthcare Conference
Elicio Therapeutics will present at the Bank of America Healthcare Conference from May 12-14, 2026. Key executives, including CEO Robert Connelly, will discuss the company's innovative immunotherapy pipeline. Elicio's lead program, ELI-002, targets mKRAS-positive cancers and has shown promising clinical results. The presentation will be available via webcast for 90 days.
Read more →ELTXElicio Therapeutics Reports Inducement Grants
Elicio Therapeutics announced the granting of 21,210 inducement stock options to a new employee as part of its hiring strategy. The options, approved by the Compensation Committee, allow the purchase of shares at $11.78 each and vest over four years. Elicio is focused on developing novel immunotherapies for high-prevalence cancers, leveraging its Amphiphile technology.
Read more →ELTXElicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
Elicio Therapeutics reported its financial results for 2025, highlighting progress in the Phase 2 AMPLIFY-7P trial for ELI-002 7P targeting KRAS-mutant pancreatic cancer. The company noted fewer disease progressions than projected and plans to expand ELI-002 7P's development. Despite a net loss of $39.5 million, Elicio's cash reserves are expected to sustain operations into Q3 2026.
Read more →ELTXElicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Elicio Therapeutics will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026. CEO Robert Connelly and CSO Pete DeMuth will discuss the company's advancements in immunotherapy for cancer treatment. Elicio focuses on off-the-shelf therapies targeting mKRAS-positive cancers, with promising clinical trial data.
Read more →ELTXElicio Therapeutics Reports Inducement Grants - January 16, 2026
Elicio Therapeutics announced the grant of 22,400 inducement stock options to two new employees as part of their hiring process. The stock options were granted at a price of $7.81 per share and will vest over four years. Elicio is focused on developing innovative immunotherapies for high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers, with promising clinical trial results.
Read more →ELTXElicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial
Elicio Therapeutics announced promising results from its Phase 2 AMPLIFY-7P trial, where 87% of evaluated patients exhibited T cell responses targeting non-mKRAS neoantigens. This antigen spreading may enhance the effectiveness of their ELI-002 7P immunotherapy by promoting broader tumor-specific immunity. The findings align with earlier Phase 1 results, indicating potential for durable clinical responses.
Read more →ELTXElicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
Elicio Therapeutics has announced the appointment of Marc J. Wolfgang as Chief Technology Officer. With an extensive background in biopharmaceutical operations, Wolfgang is expected to enhance the company’s technical and operational infrastructure, especially as it prepares for the late-stage development of its ELI-002 7P program. His previous roles at leading companies emphasize his qualifications in manufacturing and supply chain management relevant to Elicio's strategic goals. This transition comes as Elicio aims to advance its clinical pipeline, particularly targeting cancers related to mKRAS mutations.
Read more →ELTXElicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Elicio Therapeutics has reported its third quarter financial results for 2025, highlighting a promising trend in its Phase 2 AMPLIFY-7P study for ELI-002 7P in pancreatic ductal adenocarcinoma, with fewer than expected disease progressions and deaths. The company raised approximately $11.1 million, extending its financial runway through the anticipated primary endpoint analysis in early 2026. Additionally, Elicio presented updated data showing significant T cell responses in a majority of participants, further supporting the therapeutic potential of ELI-002 7P in treating KRAS-mutant pancreatic cancer. The company is poised to reach critical milestones, including an FDA meeting to discuss Phase 3 trial design in the near future.
Read more →ELTXElicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC
Elicio Therapeutics announced promising results from its Phase 2 AMPLIFY-7P trial for ELI-002 7P, showing 99% of patients with mKRAS pancreatic cancer had strong T cell responses. Additionally, new preclinical data for ELI-004 demonstrated over 90% tumor eradication in solid tumors. These findings will be presented at the SITC 2025 Annual Meeting.
Read more →ELTXElicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting
Elicio Therapeutics will present late-breaking clinical data from its Phase 2 AMPLIFY-7P trial and preclinical data from ELI-004 at the SITC 2025 Annual Meeting. The presentations will highlight the immunogenicity results of ELI-002 in patients with mKRAS-driven pancreatic cancer, showcasing the company's advancements in immunotherapy. The event will take place from November 5-9, 2025, in National Harbor, Maryland.
Read more →ELTXElicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial
Elicio Therapeutics announced promising preliminary results from its Phase 2 AMPLIFY-7P trial, showing that mKRAS-specific T-cell responses were induced in patients with diverse HLA backgrounds. The trial involved 89 patients, revealing a wide genetic diversity among participants. These findings suggest that ELI-002 7P could effectively target a broad patient population with pancreatic cancer, addressing significant unmet medical needs.
Read more →ELTXElicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
Elicio Therapeutics has announced an investigator-initiated Phase 1 trial for ELI-002 7P, aimed at treating pancreatic ductal adenocarcinoma. The trial, funded by the Lustgarten Foundation and led by Memorial Sloan Kettering Cancer Center, will explore the combination of ELI-002 with chemotherapy and an anti-PD1 inhibitor. The study seeks to improve patient outcomes by enhancing immune responses against this difficult-to-treat cancer.
Read more →ELTXElicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial
Elicio Therapeutics reported that 99% of evaluable patients in the Phase 2 AMPLIFY-7P trial exhibited strong mKRAS-specific T cell responses after receiving ELI-002 7P. This data aligns with previous Phase 1 results and suggests potential clinical activity, particularly in patients with minimal residual disease. The final disease-free survival analysis is expected in Q4 2025.
Read more →ELTXElicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients
Elicio Therapeutics announced the publication of updated follow-up data from its Phase 1 AMPLIFY-201 study of ELI-002 in Nature Medicine. The study showed that over two-thirds of participants with strong T cell responses had a significantly reduced risk of relapse or death. The results support the potential of Elicio's AMP platform in treating mKRAS-driven tumors, with plans for further development in other cancer indications.
Read more →ELTXElicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Elicio Therapeutics reported a positive recommendation from the Independent Data Monitoring Committee to continue its ELI-002 7P Phase 2 study in pancreatic cancer. The company secured $10 million in financing, which will support operations into early 2026. The final analysis of disease-free survival is expected in Q4 2025, with plans for a pivotal Phase 3 trial following FDA alignment.
Read more →ELTXElicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis
Elicio Therapeutics announced a positive recommendation from the Independent Data Monitoring Committee (IDMC) to continue its Phase 2 AMPLIFY-7P study of ELI-002 7P in pancreatic cancer without modifications. The IDMC confirmed a favorable safety profile, and the company anticipates a final disease-free survival analysis in Q4 2025. ELI-002 7P targets mutant KRAS-driven pancreatic cancer and may offer new treatment options.
Read more →ELTXElicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer
Elicio Therapeutics is hosting a virtual KOL event on June 25, 2025, to discuss its AMP-powered therapeutic vaccine, ELI-002, aimed at treating KRAS mutation-driven pancreatic cancer. The event will feature leading experts and provide insights into the current treatment landscape and the potential of ELI-002, which is currently in a Phase 2 trial. An interim analysis of the trial is expected in Q3 2025.
Read more →ELTXElicio Therapeutics Secures $10 Million in Financing
Elicio Therapeutics has secured a $10 million financing deal to strengthen its financial position and extend operations into the first quarter of 2026. The funding supports the ongoing AMPLIFY-7P Phase 2 trial for its lead cancer immunotherapy candidate, ELI-002, expected to produce interim analysis results in Q3 2025. This financing agreement includes a senior secured promissory note with a high interest rate and warrants for common stock. While the financing provides crucial operational support, it is accompanied by challenges such as reliance on one investor and potential uncertainties with upcoming clinical trial outcomes.
Read more →ELTXElicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Elicio Therapeutics has reported its financial results for the first quarter of 2025, indicating a net loss of $11.2 million. The company is approaching a critical interim analysis for its Phase 2 AMPLIFY-7P trial, expected in Q3 2025, for its lead product ELI-002. Additionally, Elicio has secured alignment with the FDA on the design of a Phase 3 study. The company asserts that its current financial position will sustain its operations until late 2025, allowing for further development of ELI-002, which aims to treat mKRAS-driven tumors.
Read more →ELTXElicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires
Elicio Therapeutics, Inc. has announced the granting of inducement awards to its new Chief Strategy and Financial Officer, Preetam Shah, along with two additional hires. The awards consist of stock options allowing the purchase of Elicio common stock at $4.98 per share. These options will vest over a four-year period, contingent upon the employees' continued service with the company. The move aligns with Elicio's strategy to bolster its leadership to further its development of novel immunotherapies for cancer treatment.
Read more →ELTXElicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
Elicio Therapeutics reported its financial results for 2024, highlighting significant progress in its cancer immunotherapy pipeline. The company successfully completed enrollment in its Phase 2 AMPLIFY-7P clinical trial and is preparing for an interim analysis expected in Q3 2025. Elicio has also aligned with the FDA on key aspects of the ELI-002 Phase 3 study design for treating mKRAS-positive pancreatic cancer. Despite a substantial increase in net loss compared to the previous year, Elicio strengthened its cash position to support operations into 2025.
Read more →ELTXElicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer
Elicio Therapeutics has appointed Dr. Preetam Shah as Chief Strategy and Financial Officer, effective immediately. Dr. Shah brings extensive experience from previous roles in other biotechnology firms and is expected to enhance Elicio's corporate strategies, particularly as the company prepares for an interim analysis of its Phase 2 AMPLIFY-7P study. Elicio continues to advance its promising immunotherapy, ELI-002, which targets major KRAS mutations associated with many cancers.
Read more →ELTXElicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules BOSTON
Elicio Therapeutics announced a registered direct offering worth $10 million, allowing institutional investors to purchase over 1.26 million shares and accompanying warrants at a price of $7.925 per share. The company intends to utilize the proceeds for working capital and corporate purposes. The offering, facilitated by H.C. Wainwright & Co., is expected to close around January 30, 2025, subject to standard conditions. Elicio focuses on developing novel immunotherapies, including its lead program targeting KRAS mutations.
Read more →ELTXElicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
Elicio Therapeutics has received positive feedback from the FDA regarding the design of its upcoming Phase 3 study for ELI-002, an investigational immunotherapy targeting KRAS-mutated pancreatic adenocarcinoma. This meeting indicated agreement on crucial elements like dosing and patient population. The Phase 2 study of ELI-002 is fully enrolled, with interim results expected by mid-2025. Should these results be favorable, Elicio plans to advance swiftly into Phase 3, potentially leading to regulatory submission and approval.
Read more →ELTXElicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
Elicio Therapeutics has presented updated results from the ELI-002 Phase 1 AMPLIFY-201 study at the ESMO Immuno-Oncology Congress 2024, demonstrating a 16.3-month median recurrence-free survival (mRFS) and a 28.9-month median overall survival (mOS) in patients with KRAS-mutant tumors. The study found a strong correlation between T cell responses and improved survival metrics, with ELI-002 showing a favorable safety profile. The next event-driven interim analysis from the randomized Phase 2 trial is anticipated in the first half of 2025.
Read more →ELTXElicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment Phase 2 randomized study of ELI-002 enrolled 135 patients; formal interim analysis of disease-free survival ( DFS ) expected in H1 2025 BOST
Elicio Therapeutics has announced the successful completion of patient enrollment in the Phase 2 AMPLIFY-7P study, assessing the efficacy of their ELI-002 vaccine in patients with mutant KRAS-positive pancreatic ductal adenocarcinoma. A total of 135 patients have been enrolled, and an interim analysis of disease-free survival is anticipated in the first half of 2025. Previous study results indicated a favorable safety profile and robust immune responses, yet the final effectiveness will be determined based on forthcoming data analysis. The study is crucial for evaluating ELI-002's potential as an innovative treatment for patients at high risk of relapse.
Read more →ELTXElicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Elicio Therapeutics reported its financial results for Q3 2024 and provided updates on its clinical programs. The AMPLIFY-7P Phase 2 study is on track for enrollment completion in Q4 2024, with an interim analysis expected in H1 2025. The company highlighted promising data from its ELI-002 program showing strong T cell responses in patients with KRAS mutant tumors. Despite a reported net loss of $18.8 million, Elicio has strengthened its financial position, enabling continued operations into 2025.
Read more →ELTXElicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
Elicio Therapeutics presented updated preliminary data from the Phase 1 AMPLIFY-7P clinical trial of ELI-002 at the 2024 SITC Annual Meeting. The data revealed strong and durable T cell responses targeting KRAS mutations, which correlated with improved disease-free survival in patients. A favorable safety profile was noted, with no significant adverse events reported. The Phase 2 interim analysis of disease-free survival is anticipated to be released in the first half of 2025.
Read more →ELTXElicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
Elicio Therapeutics is set to present updated Phase 1 clinical data for its cancer vaccine ELI-002 at the SITC Annual Meeting and the SU2C Innovation Summit in November 2024. These presentations will feature extended follow-up data from the AMPLIFY-7P study targeting KRAS-mutant tumors, particularly pancreatic cancer. This highlights Elicio's ongoing commitment to developing innovative immunotherapies with its AMP technology aimed at enhancing the immune system's capabilities against aggressive cancers.
Read more →ELTXElicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
Elicio Therapeutics has announced three upcoming presentations showcasing its lymph node-targeted mKRAS-specific amphiphile vaccines. Key discussions will include recent data from the Phase I AMPLIFY-7P trial, highlighting T cell responses in patients. The company is also set to present at major conferences, indicating strong engagement in the cancer research community. Financially, Elicio has raised $43 million in 2024, which will support its clinical programs into mid-2025.
Read more →ELTXElicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Elicio Therapeutics, a clinical-stage biotechnology company, is set to present at the H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024. CEO Robert Connelly will lead the presentation, which will be accessible via a live webcast for registered attendees. The company's focus is on novel lymph node-targeted immunotherapies aimed at enhancing the immune system's ability to fight aggressive cancers. Elicio's pipeline includes innovative cancer vaccines targeting specific mutations.
Read more →ELTXElicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Elicio Therapeutics reported its financial results for the second quarter of 2024, highlighting progress in its clinical programs, particularly with the ELI-002 7-peptide formulation. Preliminary data show a robust T-cell response in all participants of the AMPLIFY-7P Phase 1 trial, with continued patient enrollment for the Phase 2 trial expected to complete in Q4 2024. The company raised $43 million, funding operations into Q2 2025, though it announced the termination of the long-term follow of the AMPLIFY-201 Phase 1 study. Elicio remains optimistic about their ongoing trials and future data presentations.
Read more →ELTXElicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note BOSTON
Elicio Therapeutics has successfully closed a private placement, securing $20 million through a senior secured convertible note. The note, issued to GKCC, LLC, has a 3% interest rate and is due in February 2026. Elicio plans to utilize the funds for working capital and general corporate purposes. This financing is part of the company's strategy to advance its novel immunotherapy pipeline for cancer treatment.
Read more →ELTXElicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering BOSTON
Elicio Therapeutics has announced the pricing of an underwritten public offering amounting to approximately $11.5 million. The offering includes 500,000 shares of common stock and pre-funded warrants to purchase up to 1,800,000 shares. The raised capital is intended to advance the company's immunotherapy pipeline for cancer treatment and for general corporate purposes. The offering is anticipated to close around July 1, 2024, contingent upon customary closing conditions.
Read more →ELTXElicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P ELI-002 7P administered as a monotherapy at the Phase 2 dose shows preliminary encouraging
Elicio Therapeutics has announced preliminary findings from its ongoing AMPLIFY-7P Phase 1a study of ELI-002 7P, demonstrating encouraging disease-free survival (DFS) results in patients with mKRAS-driven pancreatic ductal adenocarcinoma. The study evaluates a 7-peptide formulation administered at a Phase 2 dose, with early data indicating positive outcomes associated with T cell responses and tumor reduction. Further updates from the trial are anticipated within 2024, alongside an interim analysis scheduled for early 2025.
Read more →ELTXElicio Therapeutics Announces Proposed Public Offering
Elicio Therapeutics, Inc. announced a proposed public offering of its common stock and accompanying warrants to raise capital for its development pipeline. The offering, which is subject to market conditions, aims to support ongoing research and general corporate purposes. A shelf registration statement has been filed with the SEC, allowing for the sale of these securities. Elicio's immunotherapy pipeline focuses on enhancing cancer treatment through innovative lymph node-targeted approaches.
Read more →ELTXElicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
Elicio Therapeutics presented preliminary data from the AMPLIFY-7P Phase 1a study of ELI-002 7P at ASCO 2024. The data demonstrated that ELI-002 7P is well tolerated and induces robust mKRAS-specific T cell responses in all patients evaluated. Notably, tumor biomarker reductions were observed in a significant proportion at the recommended Phase 2 dose. The study highlights ELI-002 7P's potential to address a critical need in treating mKRAS-driven solid tumors.
Read more →ELTXElicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Elicio Therapeutics reported its Q1 2024 financial results, highlighting significant progress on its lead drug, ELI-002. The company shared promising preliminary data from the Phase 1 trial of ELI-002, which showcases an effective immune response in patients with KRAS-driven cancers. ELI-002's clinical profile is supported by data suggesting robust T cell activity and antigen spreading. However, the company also reported an increase in net loss and a decline in cash reserves, indicating financial challenges amidst clinical advancements.
Read more →ELTXElicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
Elicio Therapeutics will present new preliminary data from its ongoing AMPLIFY-7P Phase 1/2 study at the 2024 ASCO Annual Meeting in Chicago. This study focuses on the investigational cancer vaccine ELI-002 7P, designed to stimulate immune responses in patients with mKRAS-driven solid tumors. The presentation is anticipated to provide insights into the efficacy and safety of ELI-002 7P in targeting the seven KRAS mutations common in solid tumors.
Read more →ELTXElicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
Elicio Therapeutics will present updated immunogenicity data from its ongoing Phase 1 AMPLIFY-201 study of ELI-002 at the AACR Annual Meeting. Key findings show that a significant percentage of patients developed mKRAS-specific CD4+ and CD8+ T cells, with evidence of antigen spreading targeting additional tumor mutations. Additionally, preclinical data for ELI-007 and ELI-008 indicates substantial enhancement in immune response compared to standard vaccines. The company plans to share further results from its 7-peptide formulation of ELI-002 in mid-2024.
Read more →ELTXElicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
Elicio Therapeutics reported its financial results for 2023 alongside significant corporate developments. The company has made progress in its clinical trials, particularly with ELI-002, which is now in a Phase 2 study for pancreatic ductal adenocarcinoma. Financially, Elicio faced a net loss of $35.2 million, though it ended the year with improved cash reserves of $12.9 million. The firm is optimistic about upcoming clinical data releases in 2024, following a positive reception of its research findings.
Read more →ELTXElicio Therapeutics Announces $6.0 Million Private Placement Financing
Elicio Therapeutics has announced a $6 million private placement financing via pre-funded warrants to GKCC, LLC, a board-controlled entity. Each warrant allows the purchase of shares at a minimized price, reinforcing Elicio's capital for advancing its cancer immunotherapy pipeline. The transaction is anticipated to close on March 19, 2024, pending customary conditions. Proceeds will aid in development and general corporate objectives, emphasizing Elicio's commitment to innovative cancer treatments.
Read more →ELTXElicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
Elicio Therapeutics has announced three upcoming poster presentations at the AACR Annual Meeting, scheduled for April 5-10, 2024, in San Diego. The presentations will highlight the company's immunotherapy candidates, ELI-002, ELI-007, and ELI-008, which utilize the Amphiphile technology to activate T cells targeting solid tumors. ELI-002, in particular, is designed to address KRAS mutations prevalent in various cancers including pancreatic and colorectal cancers. Elicio's proprietary Amphiphile platform aims to enhance immune responses through targeted delivery to lymph nodes, presenting significant advancements in cancer treatment.
Read more →ELTXElicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Elicio Therapeutics announced that its CEO, Robert Connelly, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The event will be accessible via a live webcast, allowing investors to follow Elicio's developments in immunotherapy. Elicio focuses on innovative treatments targeting lymph nodes to enhance immune response against aggressive cancers.
Read more →ELTXElicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
Elicio Therapeutics has announced promising preclinical data demonstrating that its TCR-T cell therapy, when combined with lymph node-targeted AMP immunotherapy, led to the complete eradication of solid tumors in murine models. This combination therapy not only enhanced anti-tumor immunity but also resulted in long-lasting protection against tumor recurrence. The findings suggest significant potential for clinical advancement of this approach, especially for tumors resistant to traditional therapies. The research has been published in Cancer Immunology Research, highlighting it as a pivotal advancement in cancer immunotherapy.
Read more →ELTXElicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
Elicio Therapeutics has announced a poster presentation at the upcoming ASCO GI Symposium for its Phase 1/2 AMPLIFY-7P study of the ELI-002 7P cancer vaccine. This investigational vaccine targets seven KRAS mutations common in pancreatic cancer and aims to improve patient outcomes by stimulating strong immune responses. The study incorporates both safety and efficacy evaluations against standard care for patients with KRAS-mutated pancreatic ductal adenocarcinoma. Elicio has reported initial positive findings from an earlier formulation of the vaccine, indicating potential for significant clinical advancements.
Read more →ELTXElicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference
Elicio Therapeutics announced its participation in the B. Riley Securities 4th Annual Oncology Conference on January 18, 2024. Key executives, including the CEO and Chief Medical Officer, will engage in a fireside chat, showcasing the company's commitment to discussing its advancements. The event underscores Elicio's role in developing novel immunotherapies aimed at treating aggressive cancers. A replay of the discussion will be made available on Elicio's website following the event.
Read more →ELTXElicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
Elicio Therapeutics has reported that the first patient has been dosed in its randomized Phase 2 AMPLIFY-7P trial for ELI-002, a cancer vaccine targeting KRAS mutations in pancreatic ductal adenocarcinoma. This investigational therapy aims to stimulate an immune response against seven KRAS mutations, which account for a significant portion of solid tumors. The company plans to present a Trial in Progress poster at the upcoming ASCO Gastrointestinal Cancers Symposium. Data from prior studies suggest that ELI-002 may effectively reduce tumor biomarkers and improve patient outcomes.
Read more →ELTXNature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic's AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002 Data showed ELI-002 administered as a monotherapy induced robust, polyfunctional and d
Elicio Therapeutics has published updated Phase 1 data from its AMPLIFY-201 study of ELI-002 in Nature Medicine, highlighting promising results in cancer immunotherapy. The study demonstrated that ELI-002 induced strong mKRAS-specific T cell responses in a significant portion of patients while showing reductions in tumor biomarkers. With plans for a randomized Phase 2 trial, ELI-002 aims to provide novel treatment options for patients with high relapse risk mKRAS-driven solid tumors such as pancreatic and colorectal cancers.
Read more →ELTXElicio Therapeutics Announces $7.0 Million Private Placement Financing
Elicio Therapeutics has announced a $7.0 million private placement financing where it will sell 1,213,000 shares at $5.81 each to GKCC, LLC. The gross proceeds will be utilized to advance its development pipeline, alongside working capital needs. The financing's closing is set for December 22, 2023, subject to customary conditions, and it includes a commitment to file a registration statement for the resale of shares. This move is part of Elicio's focus on developing novel immunotherapies for cancer treatment.
Read more →ELTXElicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
Elicio Therapeutics, a clinical-stage biotech company focused on immunotherapies for cancer, has announced that CEO Robert Connelly will present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on December 6, 2023. The company's innovative research includes novel immunotherapies aimed at enhancing immune responses in lymph nodes. A live webcast of the presentation will be available in the Investors section of their website and will remain accessible on-demand for 90 days.
Read more →ELTXElicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
Elicio Therapeutics reported its third-quarter financial results, highlighting promising data for its lead vaccine candidate, ELI-002. The phase 1a study showed a median relapse-free survival of 16.3 months and a significant reduction in the risk of progression or death associated with induced T cell responses. The company is planning to initiate a randomized Phase 2 trial for ELI-002 in early 2024, further expanding its pipeline targeting various KRAS mutations. Financially, Elicio experienced a net loss of $10.7 million, up from the previous year, with increased R&D expenses tied to clinical trials.
Read more →ELTXElicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting
Elicio Therapeutics has presented updated preliminary data from the ongoing Phase 1 study of its investigational cancer vaccine ELI-002 at the SITC 2023 Annual Meeting. The study, focusing on patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers, reported an impressive 87% of patients showing direct ex vivo mKRAS-specific T cell responses. Additionally, the new vaccine candidates ELI-007 and ELI-008 demonstrated strong tumor-antigen-specific T cell responses in preclinical models, indicating potential for broader applicability among various cancer types.
Read more →ELTXElicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting
Elicio Therapeutics has announced that it will present updated preliminary data from its Phase 1 study of ELI-002 targeting mutated KRAS at SITC 2023. Additionally, the company will share preclinical data on vaccines ELI-007 and ELI-008. These presentations will take place at the San Diego Convention Center from November 1-5, 2023. The focus is on innovative immunotherapy approaches to combat KRAS-driven cancers with potential broad clinical applications.
Read more →ELTXDocument Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference Pancreatic Cancer ELI-002 2P is an investigationa
Elicio Therapeutics announced promising preliminary results from the Phase 1 study of ELI-002, a cancer vaccine targeting KRAS mutations, at the AACR Special Conference. The data showed a notable median relapse-free survival of 16.3 months in patients with strong T cell responses, compared to just 3.9 months for those with weaker responses. This suggests a strong correlation between T cell response and clinical outcomes, supporting the drug's potential effectiveness in treating mutant KRAS-driven solid tumors. The company plans to begin a Phase 2 study of ELI-002 in early 2024.
Read more →ELTXElicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer
Elicio Therapeutics has presented updated preliminary data on its cancer vaccine ELI-002, showing promising relapse-free survival (RFS) outcomes in patients with mutant KRAS-driven solid tumors. The findings indicate that patients with a strong T cell response had not reached median RFS, compared to a median of 3.91 months for those with weaker responses. An 86% reduction in risk of progression or death was noted for patients with large T cell responses. Elicio plans to advance the treatment to a randomized phase 2 study early in 2024 in light of these encouraging results.
Read more →ELTXDocument Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines Funds will advance research into ELI-007, a mutant BRAF-pe
Elicio Therapeutics has been awarded a $2.6 million grant from the Gastro-Intestinal Research Foundation to support its research for two therapeutic cancer vaccines, ELI-007 and ELI-008. This funding is an addition to a previous $2.8 million grant and aims to advance the development of vaccines targeting mutant BRAF and p53 proteins. The vaccines utilize Elicio's unique Amphiphile platform, which targets lymph nodes to enhance immune responses against cancer. The company has already achieved several key milestones in their development process and is now poised for initial patient clinical assessments.
Read more →ELTXElicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines
Elicio Therapeutics has secured a $2.6 million grant from the GI Research Foundation to advance research into two innovative cancer vaccines, ELI-007 and ELI-008. This funding adds to a previous $2.8 million grant awarded in September 2022, emphasizing the foundation's support for Elicio's work targeting specific cancer mutations. The company aims to leverage its proprietary Amphiphile platform to enhance T cell responses against these mutations. With this financing, Elicio plans to move forward with clinical assessments of these vaccines.
Read more →ELTXElicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Elicio Therapeutics, a clinical-stage biotechnology firm, announced that its CEO, Robert Connelly, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023. The presentation is expected to highlight the company's pipeline of novel immunotherapies aimed at cancer treatment. Attendees will have access to a live webcast and an archived replay of the event for 30 days. Elicio is focused on engineering lymph node-targeted AMPlifiers and vaccines for various aggressive cancers.
Read more →ELTXElicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer
Elicio Therapeutics announced that it will present additional data from its Phase 1 study of ELI-002, a cancer vaccine candidate, at the AACR Special Conference on Pancreatic Cancer. This presentation will take place in Boston from September 27-30, 2023. ELI-002 aims to treat patients with pancreatic and colorectal cancers characterized by specific KRAS mutations. The company's proprietary AMP technology is designed to enhance immunological responses by targeting lymph nodes directly.
Read more →ELTXElicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics
Elicio Therapeutics has appointed Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics. Ms. Filoon will oversee legal affairs and compliance, while Dr. Kheoh will lead biostatistical efforts for the company's clinical trials, specifically the ongoing AMPLIFY-201 and AMPLIFY-7P trials. Their appointments come at a pivotal time as Elicio advances its lead cancer vaccine candidate, ELI-002, targeting mKRAS-driven cancers.
Read more →ELTXElicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
Elicio Therapeutics has reported its second quarter 2023 financial results alongside significant corporate updates. The company shared positive interim data on its cancer vaccine candidate ELI-002 presented at the ASCO Annual Meeting, highlighting strong T-cell activity and reductions in tumor biomarkers. Elicio successfully dosed the first patient in its AMPLIFY-7P trial and anticipates further clinical data releases later in 2023. However, the company continues to face net losses and increasing administrative expenses as it transitions to a public entity.
Read more →ELTXElicio Therapeutics Announces Publication of Preclinical Data Demonstrating AMP-CpG Adjuvant Can Induce Potent and Durable Immune Response in Epstein-Barr Virus (EBV) Infectious Disease Model
Elicio Therapeutics announced the publication of preclinical data demonstrating that its AMP-CpG adjuvant can induce strong and durable immune responses against the Epstein-Barr virus (EBV). The research showed that AMP-CpG can generate sustained EBV-specific antibodies and T cell responses, with implications for protecting against EBV-related diseases. The data, published in Nature Communications, also highlights the effectiveness of AMP-CpG in eliminating EBV+ tumor cells. This marks a significant advancement in vaccine development for EBV, which currently has no approved vaccines.
Read more →ELTXElicio Therapeutics Completes Reverse Merger and Provides a Corporate Update
Elicio Therapeutics has successfully completed its reverse merger, becoming publicly traded on Nasdaq. The company reported positive Phase 1 clinical trial results for its lead program, ELI-002, an immunotherapy targeting mutant KRAS-driven cancers. Elicio is actively enrolling patients for its Phase 1/2 study, AMPLIFY-7P, featuring a new 7-peptide formulation of ELI-002. The leadership team, including new CFO Brian Piekos, remains focused on advancing ELI-002 and developing its pipeline.
Read more →ELTXElicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO
Elicio Therapeutics announced positive interim clinical results from its Phase 1 study of ELI-002, a cancer immunotherapy aimed at patients with high relapse risk pancreatic and colorectal cancer. The study demonstrated that ELI-002 was well-tolerated, with no dose limiting toxicity reported and responses observed across all doses. The trial showed a significant increase in mKRAS-specific T cell responses, suggesting potential effectiveness in treating these high-risk patients. These findings were presented at the 2023 ASCO Annual Meeting.
Read more →ELTXElicio Therapeutics Reports Inducement Grant to New Chief Financial Officer
Elicio Therapeutics announced the inducement grant of stock options to Brian Piekos, the newly appointed Chief Financial Officer, as part of his employment agreement. This grant includes options for 75,484 shares at a price of $10.00 each, vesting over four years. Elicio is a clinical-stage biotechnology company focused on innovative immunotherapies for cancer treatment, highlighting its ambitious pipeline and growth strategy.
Read more →ELTXAngion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
Angion Biomedia Corp. has announced a 1-for-10 reverse stock split of its outstanding common shares, effective June 2, 2023. The decision was approved by stockholders at a special meeting held on May 31, 2023, and aims to satisfy Nasdaq's minimum bid price requirement of $1.00 per share. Following the stock split, Angion's shares will trade under the new symbol "ELTX." This move highlights the company's commitment to maintaining compliance with market standards as it continues to focus on developing therapies for fibrotic diseases.
Read more →ELTXElicio Therapeutics Announces Completion of Merger with Angion Biomedica
Elicio Therapeutics has successfully completed its merger with Angion Biomedica, and shares will begin trading on Nasdaq under the ticker ELTX on June 2, 2023. The company plans to focus on advancing its lead candidate, ELI-002, which aims to target mutant KRAS-driven cancers. Promising interim data for ELI-002 will be presented at the upcoming ASCO conference. The leadership team from Elicio will remain intact, steering the combined entity towards future clinical trials and product developments.
Read more →ELTXElicio Therapeutics to Present Interim Data from the Ongoing Phase 1 Study of Investigational Therapeutic Cancer Vaccine, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at
Elicio Therapeutics announced that it will present interim data from its ongoing Phase 1 study of the investigational cancer vaccine ELI-002 at the 2023 ASCO Annual Meeting. The AMPLIFY-201 trial focuses on patients with high relapse risk pancreatic and colorectal cancers driven by specific KRAS mutations. This vaccine utilizes Elicio's AMP technology to potentially enhance immune response by targeting lymph nodes. Presentation details include a discussion session scheduled for June 3, 2023. ELI-002 aims to address a critical need for effective treatments in a challenging patient group.
Read more →ELTXElicio Therapeutics Announces First Patient Dosed in Phase 1 2 Study of Lymph Node-Targeted Investigational Therapeutic Vaccine ELI-002 7P (AMPLIFY-7P) in KRAS NRAS Mutated Solid Tumors a. The 7-peptide formulation of EL
Elicio Therapeutics has announced that the first patient has been dosed in its Phase 1/2 study of the immunotherapy vaccine ELI-002 7P, targeting patients with KRAS and NRAS mutated solid tumors. This investigational vaccine is designed to combat seven common mutations that contribute to a significant portion of solid tumors. The study aims to bridge the existing 2-peptide formulation to the new 7-peptide formulation, potentially enhancing treatment options for cancer patients at high risk of relapse. Interim results from an earlier study involving a 2-peptide formulation are expected at the upcoming ASCO Annual Meeting.
Read more →ELTXElicio Therapeutics and Angion Enter into Definitive Merger Agreement Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio's proprietary lymph node-targeting Amphiphile (AMP) te
Elicio Therapeutics has entered into a definitive merger agreement with Angion Biomedica Corp, which will allow Elicio to merge with a subsidiary of Angion in an all-stock transaction. The newly combined entity will focus on advancing Elicio's technology for developing immunotherapies, particularly ELI-002, aimed at treating mKRAS-driven tumors. Shareholders from Elicio will hold a significant majority in the merged company. The deal has received unanimous approval from both companies’ boards and is expected to close in Q2 2023, pending stockholder approval.
Read more →ELTXElicio Therapeutics Announces Publication of Preclinical Data in Science Translational Medicine Demonstrating the AMP Platform Promotes Uptake of Intranasal Vaccine in the Mucosa Amplifying Immune Response
AMP-protein-based vaccines administered intranasally to mice and nonhuman primates (NHPs) were transported across the epithelial lining to the nasal-associated lymphoid tissue (NALT) and persisted in the nasal mucosa eliciting immune responses at both local and distal mucosal sit
Read more →ELTXElicio Therapeutics Receives $2.8 Million Grant from the Gastro-Intestinal Research Foundation (GIRF) to Fund Research for Two Therapeutic Cancer Vaccines
Funds will advance research into ELI-007 as a mutant BRAF-peptide vaccine and ELI-008 as a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting several mutations BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a c
Read more →ELTXElicio Therapeutics Announces Publication of Preclinical Data on ELI-005, a Lymph Node-Targeted Amphiphile Vaccine Against SARS-CoV-2
Data published in bioRxiv shows ELI-005 administration safely promotes robust cellular and humoral immunity through potent and targeted engagement of the lymph nodes in mice and non-human primates (NHPs) Prime-boost administration of ELI-005 induced potent Spike receptor binding
Read more →ELTXDocument Angion Provides Corporate Update and Reports Second Quarter 2022 Financial Results Uniondale, NY
Angion Provides Corporate Update and Reports Second Quarter 2022 Financial Results Uniondale, NY - August 15, 2022 - Angion Biomedica Corp (NASDAQ ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule the
Read more →ELTXElicio Therapeutics Presents Preclinical Data on AMP-CpG Adjuvant in Combination with EBV Vaccine at the 2022 Keystone Symposia: Viral Immunity: Basic Mechanisms and Therapeutic Applications
Data showed that vaccination with AMP-CpG combined with EBV gp350 and EBVpoly proteins delivered directly to the lymph nodes rapidly induced potent gp350-specific antibodies (IgG), EBV neutralizing antibody responses and EBV-specific T cell responses in HLA transgenic mice. The
Read more →ELTXElicio Therapeutics Presents Preclinical Data on its Lymph Node-Targeted SARS-CoV-2 Amphiphile Vaccine, ELI-005, at the 2022 Keystone Symposia on Viral Immunity: Basic Mechanisms and Therapeutic Applications
The presented data show ELI-005 elicits strong and long-lasting cellular and humoral immune responses that were maintained at significantly higher levels than comparator vaccines over 32 weeks in mice. ELI-005, containing the lymph node-targeted Amphiphile vaccine adjuvant AMP-C
Read more →ELTXElicio Therapeutics Presents Design of Ongoing AMPLIFY-201 Study in Mutant KRAS-Driven Cancers at ASCO Annual Meeting 2022
AMPLIFY-201 is a Phase 1 clinical study of ELI-002, a lymph node-targeted therapeutic cancer vaccine, in patients with mKRAS-driven cancers; the first patient was dosed at MD Anderson The novel study (NCT04853017) is designed to examine how to treat patients following surgical r
Read more →ELTXElicio Therapeutics Announces Publication of Preclinical Data Showing AMP-Peptide Vaccine in Combination with TCR-T Cell Therapy Enhances Anti-Tumor Function and Eradicates Solid Tumors
Data published in bioRxiv shows AMP-vaccination significantly enhanced TCR-T cell anti-tumor response, while also inducing epitope spread among the endogenous T cell population, leading to durable cures of solid tumors in an established, syngeneic tumor model AMP-vaccination del
Read more →ELTXDocument Angion Provides Corporate Update and Reports First Quarter 2022 Financial Results -- Ended the quarter with $73M in cash and cash equivalents sufficient to fund operations well into 2023 Uniondale, NY
Angion Provides Corporate Update and Reports First Quarter 2022 Financial Results -- Ended the quarter with $73M in cash and cash equivalents sufficient to fund operations well into 2023 Uniondale, NY - May 16, 2022 - Angion Biomedica Corp (NASDAQ ANGN), a biopharmaceutical com
Read more →ELTXElicio Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate ELI-002 in Combination with Libtayo (cemiplimab) in KRAS-Driven Tumors
The ELI-002 and Libtayo® combination will be studied in KRAS-driven tumors including Stage III and IV non-small cell lung cancer (NSCLC), Stage IV colorectal cancer (CRC) and unresectable, locally advanced or oligometastatic pancreatic ductal adenocarcinoma (PDAC) BOSTON, May 16
Read more →ELTXElicio Therapeutics Announces Appointment of Joy Seymour as Vice President, Head of Regulatory Affairs and Promotion of Dr. Peter DeMuth to Chief Scientific Officer
BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced the appointment of Joy Seymour as Vice President, Head of Regulatory
Read more →ELTXElicio Therapeutics Presents Preclinical Data on the AMP-Peptide Vaccine in Combination with TCR-T Cell Therapy for Solid Tumors at the 2022 Keystone Symposia: Emerging Cellular Therapies
Data shows that AMP-vaccination significantly enhanced TCR-T cell anti-tumor response while also inducing epitope spread among the endogenous T cell population, leading to durable cures of solid tumors in an established, syngeneic tumor model AMP-vaccination delivers cognate pep
Read more →ELTXDocument Angion Provides Corporate Update and Reports Full Year 2021 Financial Results -- Enrollment continues in Phase 2 JUNIPER trial of ANG-3070 for the treatment of patients with primary proteinuric kidney diseases -
Angion Provides Corporate Update and Reports Full Year 2021 Financial Results -- Enrollment continues in Phase 2 JUNIPER trial of ANG-3070 for the treatment of patients with primary proteinuric kidney diseases -- Ended the year with nearly $89M in cash and cash equivalents Uni
Read more →ELTXElicio Therapeutics Presents Updated Preclinical Data at Vaccines Summit Boston 2022 on ELI-005, a Lymph Node-Targeted Amphiphile Vaccine, Demonstrating It Induces Potent Cross-Reactive Cellular and Humoral Immunity to SARS-CoV-2
ELI-005 administration safely promotes robust cellular and humoral immunity through potent and targeted engagement of the lymph nodes in mice and non-human primates Prime-boost administration of ELI-005 induced long-lived and highly potent RBD-specific effector cytokine-producin
Read more →ELTXElicio Therapeutics Presents Preclinical Data on its Amphiphile-CpG Adjuvant at the STING & TLR-Targeting Therapies Summit 2022 Digital Event
AMP-CpG efficiently targets the lymph nodes to promote potent and comprehensive innate immune activation resulting in enhanced T and B cell responses with improved functionality and persistence Application of AMP-CpG enables potent anti-tumor responses in multiple settings of th
Read more →ELTXElicio Therapeutics Moves into Boston’s Seaport District and Provides Update on Programs
The Company has moved from Cambridge, MA to a new, larger space in the Seaport District, Boston’s growing biotech hub Enrollment continues for the multicenter Phase 1 AMPLIFY-201 study of the lead ELI-002 program in patients with early-stage KRAS-driven solid tumors, following s
Read more →ELTXElicio Therapeutics Presents Preclinical Data on AMP TCR-T and CAR-T Combination Therapies at the 2021 Society for Immunotherapy of Cancer Annual Meeting
Data showed Amphiphile (AMP) boosting significantly enhanced TCR-T cell anti-tumor efficacy and led to durable responses against solid tumors in an established, syngeneic tumor model AMP boosting of CD19-specific CAR-T cells led to enhanced CAR-T activation and effector function
Read more →ELTXDocument Angion Provides Corporate Update and Reports Third Quarter 2021 Financial Results --Ended the quarter with nearly $103M in cash and cash equivalents Uniondale, NY
Angion Provides Corporate Update and Reports Third Quarter 2021 Financial Results --Ended the quarter with nearly $103M in cash and cash equivalents Uniondale, NY - November 12, 2021 - Angion Biomedica Corp (NASDAQ ANGN), a late-stage biopharmaceutical company focused on the di
Read more →ELTXElicio Therapeutics Announces First Patient Dosed in the ELI-002 (AMPLIFY-201) study in KRAS-Driven Cancers
The first patient was dosed at MD Anderson as part of a multicenter clinical trial to evaluate the safety and efficacy of ELI-002, an investigational lymph node-targeted therapeutic vaccine, in patients with KRAS-driven tumors. The pioneering trial design (NCT04853017) employs b
Read more →ELTXElicio Therapeutics Presents Updated Preclinical Data at the 2021 Vaccines Summit Demonstrating that ELI-005, a Lymph Node Targeted Amphiphile Vaccine, Induces Potent Cellular and Humoral Immunity to SARS-CoV-2
ELI-005, containing the Amphiphile vaccine adjuvant AMP-CpG, induced >25-fold higher antigen-specific T cells in the peripheral blood and exhibited potent killing of antigen-positive targets in vivo that were maintained for >5 months after vaccination Vaccine responses were high
Read more →ELTXElicio Therapeutics Announces Virtual Presentation of Data on its Amphiphile-CpG Adjuvant at the Vaccines Summit 2021
CAMBRIDGE Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced that it will present preclinical data on its AMP-CpG adju
Read more →ELTXElicio Therapeutics Presents Preclinical Data on AMP TCR-T Combination Therapy in Solid Tumors at the CAR-TCR Annual Summit 2021
Data showed AMP combination with TCR-T cell therapy promotes durable responses against aggressive solid tumors in a mouse model where TCR-T cells alone have no effect AMP combination with TCR-T cell therapy induces marked T cell expansion, solid tumor infiltration, and optimal p
Read more →ELTXDocument Angion Provides Corporate Update and Reports Second Quarter 2021 Financial Results --Topline data in ANG-3777 Phase 3 study now expected to be announced in early Q4 rather than at year end -- Phase 1 data demons
Angion Provides Corporate Update and Reports Second Quarter 2021 Financial Results --Topline data in ANG-3777 Phase 3 study now expected to be announced in early Q4 rather than at year end -- Phase 1 data demonstrated ANG-3070 was well-tolerated across dose cohorts, achieving d
Read more →ELTXElicio Therapeutics Announces Initiation of Its Phase 1/2 Dose-Escalation Study of ELI-002 (AMPLIFY-201) in KRAS-Driven Cancers
Study will evaluate the safety and preliminary efficacy of ELI-002, an investigational lymph node-targeted therapeutic vaccine in patients with KRAS-driven tumors, and minimal residual disease following surgical resection Study will assess circulating tumor DNA (ctDNA) to obtain
Read more →ELTXDocument Angion Provides Corporate Update and Reports First Quarter 2021 Financial Results Uniondale, NY
Angion Provides Corporate Update and Reports First Quarter 2021 Financial Results Uniondale, NY - May 17, 2021 - Angion Biomedica Corp (NASDAQ ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule thera
Read more →ELTXDocument Angion Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results Uniondale, NY
Angion Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results Uniondale, NY - March 30, 2021 - Angion Biomedica Corp. (NASDAQ ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel sm
Read more →ELTXAngion Biomedica Corp. Announces Closing of $117 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of Underwriters' Option to Purchase Additional Shares Uniondale, NY
Closing of $117 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of Underwriters' Option to Purchase Additional Shares Uniondale, NY - February 9, 2021 - Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical com
Read more →Competitive Position
How ELTX ranks across every disease it competes inCompetitive Position is a premium feature
See how ELTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial